Guggenheim has initiated its coverage of psychedelic drug developer Cybin (NYSE:CYBN) with a Buy rating and a $35 per share ...

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

Spravato (esketamine ... is subject to a restricted distribution programme and has to be administered in certified healthcare settings. The filing is based on the results of the TRD4005 study ...

everybody's familiar with what happens with Spravato. All these docs already know it. JN: Yeah. Exactly. And it may improve just distribution. I mean, you may run into clinics that just don't ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a ...

Living Local 15 host Jessica Williams is joined by Sean Goddard, a Psychiatric Nurse Practitioner and Owner of Viking Psychiatry, to speak about the recent approval for Spravato as a monotherapy ...

In 2019, the FDA approved Spravato, "a nasal spray derived from ketamine," for treating severe depression. "But that approval came with strict guardrails to ensure patient safety," added the Post ...

Stella Mental Health in Westmont specializes in medication management, Spravato (esketamine) nasal spray, transcranial magnetic stimulation (TMS), ketamine infusion therapy, stellate ganglion ...

Are you experiencing anxiety, depression, or PTSD? We can help. Stella Mental Health in Encinitas specializes in Spravato (esketamine) nasal spray, ketamine infusion therapy, stellate ganglion ...